Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Wu H, Chen Y, Wang Z, *et al.* Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. *J Immunother Cancer* 2019;7:264. doi: 10.1186/s40425-019-0737-3

In the article titled 'Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers', there is the following errors:

In the abstract, the sentence 'Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort ($p < 0.001$)' should instead read 'Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort ($p = 0.003$)'

Additionally, in Figure 6:

- Line 5, 'HLA-DQA1' should be 'HLA-DQA2'
- Line 51–69 (from ENDRB to TIGIT), the category of these genes 'Other' should be 'Receptor'
- Line 70–75 (from ARG1 to PRF1), the category of these genes 'Receptor' should be 'Other'.

The correct Figure 6 can be seen below:

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;**8**:e0737-3corr1. doi:10.1136/jitc-2020-0737-3corr1